Form 4: Bicara Therapeutics Chief Legal Officer Lara Meisner Reports Stock Sales and Option Exercises
SEC Form 4
Lara Meisner, Chief Legal Officer of Bicara Therapeutics, executed stock sales and option exercises on March 14, 2025, according to a Form 4 filing.
Summary
- On March 14, 2025, Lara Meisner, the Chief Legal Officer of Bicara Therapeutics, engaged in transactions involving the company's stock.
- Meisner exercised stock options to acquire 79,146 shares of common stock at a price of $5.45 per share.
- Simultaneously, Meisner sold 48,526 shares at a weighted average price of $12.688, with individual sales ranging from $12.05 to $13.04.
- Additionally, she sold 30,620 shares at a weighted average price of $13.2434, with individual sales ranging from $13.05 to $13.55.
- Following these transactions, Meisner directly owns 0 shares of common stock.
- Meisner also holds options to purchase 107,187 and 67,119 shares of common stock at an exercise price of $5.45.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports transactions by an officer under a pre-existing trading plan. It doesn't inherently indicate a positive or negative outlook for the company.
Industry Context
Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking to understand management's perspective on the company's stock.
Key Dates
| Date | Description |
|---|---|
| 2023-12-14 | Start date for vesting of 30,246 shares underlying stock options in sixteen equal quarterly installments. |
| 2024-11-13 | Date of adoption of Rule 10b5-1 trading plan. |
| 2024-11-27 | 25% of the shares underlying this option vested on November 27, 2024, with the remainder vesting in twelve equal quarterly installments thereafter. |
| 2025-03-14 | Date of stock option exercise and stock sales. |
| 2033-12-14 | Expiration date of stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.